Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial(§)

OBJECTIVES: Cobicistat (COBI) enhances atazanavir (ATV) pharmacokinetic parameters similarly to ritonavir (RTV) in both healthy volunteers and HIV-infected adults. Primary efficacy and safety outcomes of this Phase 3, international, randomized, double-blind, double-dummy, active-controlled trial in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallant, Joel, Moyle, Graeme, Berenguer, Juan, Shalit, Peter, Cao, Huyen, Liu, Ya-Pei, Myers, Joel, Rosenblatt, Lisa, Yang, Lingfeng, Szwarcberg, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543662/
https://www.ncbi.nlm.nih.gov/pubmed/27774892
http://dx.doi.org/10.2174/1570162X14666161021102728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543662/
https://www.ncbi.nlm.nih.gov/pubmed/27774892
http://dx.doi.org/10.2174/1570162X14666161021102728

Ejemplares similares